PCI has been one of the most common choice of treatments for patients with coronary artery disease, and studies indicated that intensive statin treatment before PCI could reduce adverse events as comparing to the placebo. In China, statin with regular dose is currently applied to the patients admitted for Non-ST-elevation acute coronary syndrome (ACS). Here we hypothesize that intensive statin treatment with arovastatin before PCI could further reduce clinical adverse events.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
300
patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
Ruijin Hospital, Dept. of Cardiology
Shanghai, Shanghai Municipality, China
RECRUITINGThe primary end point was the composite of major adverse cardiac events (MACE), including cardiac death, non-fatal reinfarction, and target vessel revascularization (TVR) at one-year clinical follow-up after randomization.
Time frame: one year
rate of peri-procedural myocardial infarction
Time frame: 30days
MACE at 30d after randomization 3. changes of left ventricular function at 30d after randomization
Time frame: 30 days
changes of left ventricular function at 30d after randomization
Time frame: 30 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.